Contrasting DARA Biosciences (DARA) and NOVAN INC (NASDAQ:NOVN)

DARA Biosciences (NASDAQ: DARA) and NOVAN INC (NASDAQ:NOVN) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Earnings & Valuation

This table compares DARA Biosciences and NOVAN INC’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
DARA Biosciences N/A N/A N/A N/A N/A
NOVAN INC $768,999.00 82.86 -$49.04 million ($7.93) -0.50

DARA Biosciences has higher revenue, but lower earnings than NOVAN INC.

Analyst Recommendations

This is a summary of current ratings and price targets for DARA Biosciences and NOVAN INC, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DARA Biosciences 0 0 0 0 N/A
NOVAN INC 0 1 3 0 2.75

NOVAN INC has a consensus target price of $17.24, suggesting a potential upside of 332.14%. Given NOVAN INC’s higher probable upside, analysts clearly believe NOVAN INC is more favorable than DARA Biosciences.

Institutional and Insider Ownership

8.7% of NOVAN INC shares are held by institutional investors. 10.7% of NOVAN INC shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares DARA Biosciences and NOVAN INC’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
DARA Biosciences -228.42% -145.61% -100.38%
NOVAN INC N/A -194.61% -99.61%

Summary

NOVAN INC beats DARA Biosciences on 7 of the 8 factors compared between the two stocks.

About DARA Biosciences

DARA BioSciences Inc is specialty pharmaceutical company based in the United States. The Company’s primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia), Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy. The Company is a subsidiary of Midatech Pharma Plc.

About NOVAN INC

Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company’s formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.

What are top analysts saying about DARA Biosciences Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DARA Biosciences Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit